Theravance Biopharma (TBPH) Net Income Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 32.79% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 60.43% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -46.86% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 13.80% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 19.97% |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -3.84% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 47.10% |
| 10 | Theravance Biopharma | 823.54 Mn | 428.87 Mn | - | 39.18% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 39.18% |
| Dec 31, 2025 | -157.75% |
| Sep 30, 2025 | -84.27% |
| Jun 30, 2025 | 43.96% |
| Mar 31, 2025 | -42.13% |
| Dec 31, 2024 | -3.00% |
| Sep 30, 2024 | -37.79% |
| Jun 30, 2024 | -49.29% |
| Mar 31, 2024 | -54.84% |
| Dec 31, 2023 | 51.69% |
| Sep 30, 2023 | 50.47% |
| Jun 30, 2023 | 37.11% |
| Mar 31, 2023 | 35.69% |
| Dec 31, 2022 | 27.23% |
| Sep 30, 2022 | 161.42% |
| Jun 30, 2022 | 35.02% |
| Mar 31, 2022 | 30.35% |
| Dec 31, 2021 | 35.97% |
| Sep 30, 2021 | 32.89% |
| Jun 30, 2021 | 32.10% |
| Mar 31, 2021 | 28.15% |
| Dec 31, 2020 | 4.69% |
| Sep 30, 2020 | -3.26% |
| Jun 30, 2020 | 1.74% |
| Mar 31, 2020 | -8.34% |
| Dec 31, 2019 | 0.86% |
| Sep 30, 2019 | -19.83% |
| Jun 30, 2019 | 5.51% |
| Mar 31, 2019 | -19.86% |
| Dec 31, 2018 | -3.84% |
| Sep 30, 2018 | -7.90% |
| Jun 30, 2018 | 5.00% |
| Mar 31, 2018 | -15.29% |
| Dec 31, 2017 | -10.56% |
| Sep 30, 2017 | -7.06% |
| Jun 30, 2017 | -4.42% |
| Mar 31, 2017 | -2.86% |
| Dec 31, 2016 | -15.17% |
| Sep 30, 2016 | 6.14% |
| Jun 30, 2016 | -6.63% |
| Mar 31, 2016 | -9.42% |